FLT4 and neoplasm: Recombinant human vascular endothelial inhibitors inhibit tumor lymphatic vessel production and lymphatic metastasis by inhibiting the expression of VEGF-C and VEGF-D in tumor tissues, decreasing the activation of VEGFR-3 in tissues suppressing the VEGF-C and VEGF-D/VEGFR-3 signal pathways [11].